Sansure Biotech Balance Sheet Health
Financial Health criteria checks 5/6
Sansure Biotech has a total shareholder equity of CN¥7.5B and total debt of CN¥404.6M, which brings its debt-to-equity ratio to 5.4%. Its total assets and total liabilities are CN¥8.6B and CN¥1.2B respectively. Sansure Biotech's EBIT is CN¥39.1M making its interest coverage ratio -0.1. It has cash and short-term investments of CN¥4.7B.
Key information
5.4%
Debt to equity ratio
CN¥404.56m
Debt
| Interest coverage ratio | -0.1x |
| Cash | CN¥4.72b |
| Equity | CN¥7.46b |
| Total liabilities | CN¥1.17b |
| Total assets | CN¥8.63b |
Recent financial health updates
Recent updates
Is Sansure Biotech (SHSE:688289) A Risky Investment?
Sep 12
Sansure Biotech Inc. (SHSE:688289) Investors Are Less Pessimistic Than Expected
Aug 21Sansure Biotech (SHSE:688289) May Have Issues Allocating Its Capital
Jun 03Why Sansure Biotech's (SHSE:688289) Soft Earnings Are Just The Beginning Of Its Problems
May 03Sansure Biotech Inc.'s (SHSE:688289) Business Is Trailing The Industry But Its Shares Aren't
Apr 26Sansure Biotech's (SHSE:688289) Returns On Capital Are Heading Higher
Feb 28Financial Position Analysis
Short Term Liabilities: 688289's short term assets (CN¥5.9B) exceed its short term liabilities (CN¥671.0M).
Long Term Liabilities: 688289's short term assets (CN¥5.9B) exceed its long term liabilities (CN¥496.8M).
Debt to Equity History and Analysis
Debt Level: 688289 has more cash than its total debt.
Reducing Debt: 688289's debt to equity ratio has increased from 0% to 5.4% over the past 5 years.
Debt Coverage: 688289's debt is well covered by operating cash flow (24.1%).
Interest Coverage: 688289 earns more interest than it pays, so coverage of interest payments is not a concern.